TRIM24, through PI3K/AKT/NF-κB signaling, controls the expression of the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT), contributing to increased resistance to temozolomide, the standard chemotherapeutic agent for glioblastoma [33]. Here, MGMT is linked to glioblastoma.